Abstract Human Papillomavirus (HPV) is a major global health concern due to its strong association with cervical cancer in women and oropharyngeal cancer in men. With 200+ related viruses, persistent infection with high-risk genotypes can drive malignant transformation. Cervical cancer remains the 4th most common cancer in women, with around 660,000 new cases and 350,000 deaths in 2022 94% occurring in low- and middle-income countries. Early screening, vaccination, and timely treatment are key to reducing this burden.Innovative Diagnostic Platforms Genes2Me delivers advanced HPV detection through two powerful systems: OnePCR System - A fully automated Sample-IN Result OUT platform that integrates extraction and real-time PCR in one cartridge. It detects up to 20 targets per sample with zero pipetting steps and provides results in around 100 minutes. Rapi-Q and Rapi-X16 System - A semi-POCT high-throughput solution enabling extraction of up to 16 samples simultaneously and multiplex PCR in 8 tube format, offering scalability and precision for busy laboratories. Comprehensive HPV Genotyping Panels Genes2Me HPV assays use multiplex real-time PCR with fluorescent probes for accurate genotype differentiation. High-Risk Panel (Tube 1): HPV16 (HEX), HPV18 (FAM), 12 pooled HR genotypes (Texas Red); beta-Actin internal control. Low Cy5 internal control. Expanded Low/Medium Panel (Tube 3): 14 genotypes categorized into FAM / HEX / Texas Red groups with Cy5 internal control. Citation Format: Bahadur Singh Gurjar, Giulliana Tessarin, Nishant Kumar, Namrata Erande. Advanced OnePCR HPV panel: Fast POCT platform covering complete high, medium Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 217.
Gurjar et al. (Fri,) studied this question.